Literature DB >> 33664206

Serotonergic therapy in epilepsy.

Frank G Gilliam1, Hrvoje Hecimovic2, Matthew S Gentry3.   

Abstract

PURPOSE OF REVIEW: The serotonergic system is implicated in multiple aspects of epilepsy, including seizure susceptibility, sudden unexpected death in epilepsy (SUDEP), and comorbid depression. Despite the complexity of serotonin's effects on various neuronal networks, ongoing research provides considerable insight into the role of serotonin in human epilepsy. This review explores the potential roles of serotonergic therapies to improve clinical outcomes in epilepsy. RECENT
FINDINGS: In recent decades, research has markedly increased our knowledge of the diverse effects of serotonin on brain function. Animal models of epilepsy have identified the influence of serotonin on seizure threshold in specific brain regions, serotoninergic augmentation's protective effects on terminal apnea and mortality in SUDEP, and mechanisms underlying behavioral improvement in some models of comorbid depression. Human clinical studies are largely consistent with animal data but the translation into definitive treatment decisions has moved less rapidly.
SUMMARY: Evidence for serotonergic therapy is promising for improvement in seizure control and prevention of SUDEP. For some epilepsies, such as Dravet syndrome, basic research on serotonin receptor agonists has translated into a positive clinical trial for fenfluramine. The cumulative results of safety and efficacy studies support the routine use of SSRIs for comorbid depression in epilepsy.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33664206      PMCID: PMC8478129          DOI: 10.1097/WCO.0000000000000901

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  78 in total

1.  Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.

Authors:  Kenneth Alper; Kelly A Schwartz; Russell L Kolts; Arif Khan
Journal:  Biol Psychiatry       Date:  2007-01-16       Impact factor: 13.382

2.  A reappraisal of mortality after epilepsy surgery.

Authors:  Michael R Sperling; Suzanne Barshow; Maromi Nei; Ali A Asadi-Pooya
Journal:  Neurology       Date:  2016-04-27       Impact factor: 9.910

3.  Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study.

Authors:  Philippe Ryvlin; Lina Nashef; Samden D Lhatoo; Lisa M Bateman; Jonathan Bird; Andrew Bleasel; Paul Boon; Arielle Crespel; Barbara A Dworetzky; Hans Høgenhaven; Holger Lerche; Louis Maillard; Michael P Malter; Cecile Marchal; Jagarlapudi M K Murthy; Michael Nitsche; Ekaterina Pataraia; Terje Rabben; Sylvain Rheims; Bernard Sadzot; Andreas Schulze-Bonhage; Masud Seyal; Elson L So; Mark Spitz; Anna Szucs; Meng Tan; James X Tao; Torbjörn Tomson
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

Review 4.  Risks and predictive biomarkers of sudden unexpected death in epilepsy patient.

Authors:  Philippe Ryvlin; Sylvain Rheims; Samden D Lhatoo
Journal:  Curr Opin Neurol       Date:  2019-04       Impact factor: 5.710

5.  Successful use of fenfluramine as an add-on treatment for Dravet syndrome.

Authors:  Berten Ceulemans; Marc Boel; Katrien Leyssens; Carolin Van Rossem; Pieter Neels; Philippe G Jorens; Lieven Lagae
Journal:  Epilepsia       Date:  2012-05-03       Impact factor: 5.864

6.  A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome.

Authors:  Lieven Lagae; An-Sofie Schoonjans; Arnold R Gammaitoni; Bradley S Galer; Berten Ceulemans
Journal:  Epilepsia       Date:  2018-08-26       Impact factor: 5.864

Review 7.  Chemoreception and asphyxia-induced arousal.

Authors:  Patrice G Guyenet; Stephen B G Abbott
Journal:  Respir Physiol Neurobiol       Date:  2013-04-19       Impact factor: 1.931

8.  Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants.

Authors:  Kai Uwe Kühn; Boris B Quednow; Markus Thiel; Peter Falkai; Wolfgang Maier; Christian E Elger
Journal:  Epilepsy Behav       Date:  2003-12       Impact factor: 2.937

Review 9.  Serotonin and sudden unexpected death in epilepsy.

Authors:  Alexandra N Petrucci; Katelyn G Joyal; Benton S Purnell; Gordon F Buchanan
Journal:  Exp Neurol       Date:  2019-12-19       Impact factor: 5.330

10.  Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.

Authors:  Lieven Lagae; Joseph Sullivan; Kelly Knupp; Linda Laux; Tilman Polster; Marina Nikanorova; Orrin Devinsky; J Helen Cross; Renzo Guerrini; Dinesh Talwar; Ian Miller; Gail Farfel; Bradley S Galer; Arnold Gammaitoni; Arun Mistry; Glenn Morrison; Michael Lock; Anupam Agarwal; Wyman W Lai; Berten Ceulemans
Journal:  Lancet       Date:  2019-12-17       Impact factor: 79.321

View more
  1 in total

Review 1.  Serotonin receptors in epilepsy: Novel treatment targets?

Authors:  Jo Sourbron; Lieven Lagae
Journal:  Epilepsia Open       Date:  2022-02-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.